ASLAN Pharmaceuticals Limited (ASLN) Social Stream

Featured Post From StockTwits About ASLN

$ASLN Key results from MAD, a P1b trial of ASLAN004 in Atopic Dermatitis, are expected at the end of 3Q21. At Interim Analysis (March 2021), ASLAN004 induced at least a 50% improvement in 89% of patients at 8 weeks. Interestingly, that's just one percentage point behind $FBRX's FB-401, which demonstrated a 50% improvement or better in 90% (18/20) patients at 12 weeks. Ah, but the plot thickenings. P2 results for FB-401 are expected any day now. It seems we have a bit of a horse race here, with ASLN on the outside and trailing by a nose.